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Synopsis
Proton magnetic resonance spectroscopy (1H-MRS) provides tissue metabolic information in vivo.
This article reviews the role of MRS-determined metabolic alterations in lesions, normal appearing
white matter, gray matter, and spinal cord in advancing our knowledge of pathological changes in
multiple sclerosis (MS). In addition, the role of MRS in objectively evaluating therapeutic efficacy
is reviewed. This potential metabolic information makes MRS a unique tool to follow MS disease
evolution, understanding its pathogenesis, evaluating the disease severity, establishing a prognosis,
and objectively evaluating the efficacy of therapeutic interventions.
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Introduction
Conventional magnetic resonance imaging (cMRI) is exquisitely sensitive in visualizing
multiple sclerosis (MS) lesions in brain and spinal cord, but has limited pathologic specificity.
Also, cMRI is limited in the detection of subtle, disease-related changes in the normal-
appearing white matter (NAWM)1. This limitation can be overcome to some extent by
combining MRI with magnetic resonance spectroscopy (1H-MRS) which allows detection of
tissue biochemical changes for improved pathologic specificity. Since biochemical changes
precede anatomical changes, MRS detects tissue pathologic changes even before the
appearance of lesions on cMRI2. The unique biochemical information provided by 1H-MRS
also complements the information from advanced MRI techniques such as magnetization
transfer (MT) and diffusion tensor (DT) MRI in providing a more detailed and specific
pathological information. This in turn allows to follow MS disease evolution, better understand
its pathogenesis, evaluate the disease severity, establish a prognosis, and objectively evaluate
the efficacy of therapeutic interventions3-5.
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This review is divided into three major sections: 1) brief introduction to MRS, 2) review of
MRS and its application to MS lesions, NAWM, gray matter, and spinal cord, and 3) role of
MRS in clinical trials. Because of the large number of publications on MRS in MS, wherever
possible, we have referenced more recent and relevant review articles.
Magnetic Resonance Spectroscopy
In contrast to MRI, which mainly relies on proton (1H), MRS can be performed using variety
of nuclei. Of all these nuclei, 1H and 31P are most commonly employed for MRS studies. For
a number of reasons that include sensitivity and hardware considerations, 1H-MRS is the
common choice for investigating neurological disorders. 1H-MRS provides access to a large
number of biomolecules or metabolites such as N-acetylaspartate (NAA; some authors refer
to it as NA to acknowledge that the NAA peak has contributions from N-acetylaspartate and
other N-acetyl moieties such as N-acetyl aspartyl glutamate [NAAG]. In this review NA and
NAA are used interchangeably), choline (Cho), creatine (Cr), myoinositol (mI), glutamate
(Glu) and glutamine (Gln), macromolecules, lipids and lactate (Lac). The positions of
metabolite peaks in the spectrum, expressed as parts per million (ppm), are independent of the
magnetic field strength. NAA is an amino acid derivative synthesized in neurons and
transported down axons and its main resonance appears at 2.02 ppm. NAA is generally thought
to be a specific marker of neurons, axons, and dendrites6. On this basis, reduced NAA
concentration is generally interpreted as neuronal/axonal dysfunction and/or loss. This has been
confirmed by 1H-MRS and histology studies on biopsied samples7. In general, Glu and Gln
are not resolved well even at 3.0 T and combination of resonances from these two is commonly
referred to as Glx. The resonances from Glx appear between 2.1 and 2.4 ppm. While some
studies have focused on the evaluation of the total Glu and Gln levels under pathological
conditions, other studies have employed spectral editing methods to resolve the Glu resonance.
Recently Hurd et al.8 have used a modified conventional spectral localization technique in
which data is collected over multiple echo times (TE). This method detects a single-line Glu
resonance at 2.35 ppm. Srinivasan et al.9 have shown elevated Glu concentrations in acute
lesions (P = 0.02) and NAWM (P = 0.03), with no significant elevation in chronic lesions (P
= 0.77) in MS patients compared to normal subjects. The primary resonance of Cr occurs at
3.0 ppm and has contributions both from creatine and phosphocreatine. Elevated Cr levels may
represent gliosis7. Cho signals at 3.2 ppm have contributions from multiple molecules that
include phosphorylcholine, glycerophosphorylcholine, and choline plasmalogen and a very
minor contribution from acetylcholine and choline10. Cho peak appears to reflect cell-
membrane metabolism3. Also, elevated Cho concentration represents heightened cell-
membrane turnover as seen in demyelination, remyelination, inflammation and gliosis in MS
patients3. mI exhibits two resonances, at 3.5 ppm and 4.06 ppm. Due to its proximity to tissue
water resonance, the amplitude of the 4.06-ppm peak is affected by the degree of water
suppression and is not considered to be a reliable indicator of mI concentration. Brain osmolyte
mI appears to be glia specific and it is not found in neurons11. Also, mI is a precursor of
phospholipid membrane constituents, and its concentration is affected by the formation and
breakdown of myelin. Lac is generally seen as a doublet that resonates at 1.33 ppm. It is the
end product of anaerobic glycolysis and is not commonly observed in normal brain. It is
increased in acute MS lesions and is related to macrophage activation after membrane
breakdown. Lipids along with macromolecules (referred to as lipids for brevity) appear as
broad peaks and resonate between 0.8 and 1.5 ppm. In healthy tissues, there should be very
weak lipid peaks in the spectrum unless contaminated by subcutaneous fat from non-neural
tissues. These peaks have been reported in MS and thought to represent demyelination/
remyelination2. By measuring the concentration changes in brain metabolites, MRS has
provided evidence of early pathology and myelin damage/repair in MS that is not evident on
cMRI12, 13.
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Acquisition
1H-MRS can be acquired with spatial information preserved (localized 1H-MRS), as is most
commonly done, or obtain from the whole brain by sacrificing spatial information14. Point
resolved spectroscopy (PRESS)15 and stimulated echo acquisition mode (STEAM)16 are the
two most commonly used localization techniques in 1H-MRS. Spectral contamination from
extrameningeal tissues is minimized by suppressing the signals from the outer volume17.
Figure 1 demonstrates the placement of eight outer volume suppression bands. The PRESS
localization provides better signal-to-noise ratio (SNR) compared to STEAM technique.
However, STEAM allows shorterTE- than PRESS.
Localized 1H-MRS is acquired in either a single voxel or multi-voxel mode. In single voxel
MRS, spectral data are acquired from one location at a time. The volume of this region is
typically 1 to 8 cm3. This approach involves shorter acquisition and processing times. High-
quality spectrum is relatively easy to acquire in this mode. Multi-voxel mode, also referred to
as 1H-MRS imaging (1H-MRSI) or chemical shift imaging (CSI) allows simultaneous
acquisition of 1H-MRS data from multiple voxels and allows mapping regional distribution of
metabolite concentrations and generate metabolic images. Multi-voxel MRS can be acquired
in 2D or 3D and generally offers superior spatial resolution (< 1 cm3) compared to single voxel.
Generally, 1H-MRSI is acquired from a volume that is prelocalized using either PRESS or
STEAM. It is also possible to acquire 1H-MRSI without any prior volume or slab localization
(see, for example, Sharma et al.18). 1H-MRSI involves relatively long acquisition times, which,
however, can be considerably shortened by reduced k-space encoding19. One way of
accelerating 1H-MRSI acquisition is to employ fast spectral-spatial encoding by using echo-
planar-based techniques20,21. With multi-slice and multi echo sequences, it is possible to
acquire spectra from whole brain21 within reasonable scan times. Combining EPI-based
techniques with recent advances in parallel MRI, such as sensitivity encoding (SENSE)22 or
generalized autocalibrating partially parallel acquisitions (GRAPPA)23 with radiofrequency
(RF) coil arrays can further accelerate 1H-MRSI data acquisition24-26. However, the data
acquired with these approaches generally suffers from reduced SNR. Determination of absolute
metabolite concentration is also somewhat problematic with parallel acquisition schemes.
1H-MRS can be acquired at either long or short TE. Long TE 1H-MRS provides a well-defined
baseline by suppressing peaks arising from short T2 metabolites, such as lipids and
macromolecules, and makes spectral quantification simpler and more robust. Long TE 1H-
MRS may be preferable if the interest is in the detection of the three major resonances: NAA,
Cr, and Cho. Because of their relatively short T2 relaxation times, signals from metabolites,
such as Glx, lipids, macromolecules and other myelin breakdown products can be detected
only at short TE. Even though the broad spectral baseline in short TE 1H-MRS makes the
spectral quantification more difficult, this approach has the potential to provide important
information about altered tissue biochemistry that may not be available at long TE4. There is
an increasing interest in short TE 1H-MRSI for visualizing short T2 metabolites, which should
result in improved pathological characterization of tissues3. As an example, single voxel
spectra acquired at 3 T with short and long TE, with signal mostly localized to white matter of
normal brain, are shown in Figure 2.
The macromolecular and lipid resonances exhibit significant overlap with the other
metabolites. By nulling the metabolite resonances with an inversion recovery sequence, it is
possible to improve the detection of these short TE resonances. This method was employed by
Mader et al. 27 for separating lipids from other metabolites in acute MS lesions.
While localized techniques can be used to acquire spectrum from the volume of interest (VOI),
non-localized sequence can provide MRS from the entire head. The strong broad lipid signals
arising from non-brain tissues obscure the resonances from other metabolites. However, by
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subtracting the data acquired with and without NAA nulling (through an inversion recovery
sequence), it is possible to remove/minimize strong lipid signals and visualize resonances from
other metabolites14. Because NAA is restricted to neurons/axons, it is implicitly localized to
brain. However, the presence of other resonances in non-brain tissues, compromises the
quantification of metabolites such as Cr. Thus this approach is reliable only when quantifying
the whole brain NAA (WBNAA) concentration14. Due to severe magnetic field
inhomogeneities present at air-tissue interfaces this technique captures about 90% of the NAA
signal intensity in the brain28. Albeit WBNAA measurements do not provide any information
about the spatial distribution of metabolite concentrations, this approach eliminates image
registration problems from scan-to-scan in serial studies. The reproducibility of WBNAA
levels across institutions and MR scanners and field strengths has been shown to be
satisfactory29. WBNAA measurements can be used to quantify the global neuronal and axonal
injury to monitor the effect of neuroprotective agents in MS 30.
Quantification
The inherently quantitative nature of MRS allows objective monitoring of disease state and
response to therapeutic intervention. However, this requires accurate spectral quantification.
Expressing the metabolite levels as a ratio relative to Cr is one of the most common and simplest
ways of spectral quantification. However, the interpretation of the metabolite ratios becomes
equivocal if the concentration of Cr varies with pathology2. In addition, representing brain
metabolite concentrations as ratios does not provide complete information and could lead to
significant errors31, 32. Therefore absolute quantification of metabolite concentrations is
highly desirable for proper interpretation of the MRS data. Nevertheless the NAA/Cr ratio is
commonly used in MS 33. Among the methods for estimating the absolute metabolite
concentrations, use of internal water as a standard has been shown to provide acceptable
accuracy and inter-laboratory reproducibility2, 34. However, this method depends on
knowledge of water distribution and relaxation times in different tissues. Absolute
concentrations can also be measured using the LCModel.35 This method analyzes the in
vivo spectrum as a linear combination of spectra from individual metabolites contained in a
solution (model spectrum). The model spectrum is acquired using the same sequence as that
used for in vivo spectra and provides the maximum prior knowledge for the spectral analysis.
LCModel uses a nearly model-free constrained regularization method that automatically
accounts for the fitted baseline and spectral lineshape to be consistent with the data36.
Usually, the 1H-MRSI quantification procedures involve extensive computational time, and in
some cases, significant human intervention. Currently, the most commonly used quantification
methods are based on line fitting using a non linear least square optimization, such as the
Levenberg-Marquardt algorithm35, 37-39. The relatively long computational time becomes
even more problematic when considering 3D 1H-MRSI and scans from multi-center clinical
trials where a large amount of data needs to be processed. For 1H-MRSI to become a routine
clinical tool, complete automation of quantification procedures and reduction of processing
times close to real-time are necessary. The processing time could be reduced by using high
performance computing environment. However, this is expensive, involves development of
complicated algorithms, and is not an option in routine laboratory/clinical settings. Another
approach is to develop fast methods, such as those based on artificial neural networks (ANN).
ANN has been used to develop automated methods to quantify 1H-MRS data40, 41. However,
these techniques are limited to either single voxel 1H-MRS or magnitude spectral data acquired
at long TE using lineshapes that may not be completely appropriate42. Recently, Bhat et al.
43 have employed radial basis function neural networks (RBFNN) to demonstrate the
feasibility of quantifying short TE, phased 1H-MRSI. This method is, however, limited to
ratios, and thus does not allow absolute concentrations to be measured.
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A number of excellent software packages, both free and commercial, are available for spectral
quantification. The most commonly used analysis packages include LCModel 35, jMRUI 44,
and MIDAS 45. Most of these packages involve minimal human intervention and are capable
of providing absolute concentrations, but involve long processing times. Different analysis
methods and their strengths and weaknesses in computing absolute brain metabolite
concentrations were recently reviewed 31.
Due to relatively large spectroscopic voxels, spectra have contributions from different types
of brain tissues, particularly cerebrospinal fluid (CSF). For accurate estimation of metabolite
concentrations, it is important to determine the relative volumes of each tissue that contributes
to a given spectroscopic voxel. This requires combining the MRSI data with tissue
segmentation, based on the high resolution MRI data37.
Application of MRS to MS
Lesions
There is a general consensus that chronic MS lesions exhibit reduced NAA levels, indicating
neuronal/axonal loss. This is particularly true in those lesions that also appear hypointense on
T1-weighted images (also commonly referred to as “black holes”46). In one study, metabolite
concentrations from chronic lesions of patients with relapsing-remitting (RR)MS (n=9),
secondary progressive (SP)MS (n=10), primary progressive (PP)MS (n=6), and benign MS
(BMS) (n=5) were measured and compared with those from white matter of a normal control
group (n=9)47. A highly significant reduction in NA (the sum of NAA and NAAG) was found
in RRMS, PPMS, and SPMS patients compared to controls. However, in patients with BMS
there was no significant difference in NA compared to controls. A significant inverse
correlation between NA from lesions in MS patients and disability was observed (r=-0.364,
0.05>P>0.02)47. Increased Cr and Cho levels were also observed in lesions, suggesting (a)
ongoing gliosis and remyelination in isointense lesions on T1-weighted MR images and (b)
membrane turnover (de- and remyelination) 48.
Acute MS lesions, as detected by gadolinium (Gd) enhancement, demonstrate a range of
abnormalities on 1H-MRS. These abnormalities include reduced NAA, increased Cho, and
presence of lipids2, 49-52. Histopathology on biopsied brain tissues demonstrates reduced
NAA levels even in the acute phase of the disease53. This could be the result of axonal loss or
reflect reversible axonal dysfunction due to functional impairment52, 54-56. Accordingly,
serial MRI (with Gd administration) and 1H-MRSI studies showed transient changes in NAA
levels in some acute lesions, which recovered with time2. Narayana et al.2 have observed that
metabolite levels, including NAA, reach their minimum value when lesion volume reaches its
maximum. This suggests that the observed decrease in metabolite concentrations, at least
partially, can be attributed to resolution of edema within the lesions and is not solely due to
compromised tissue metabolism. Cho levels are shown to increase in acute MS lesions2, 51,
57, as well as Lac and mI resonance intensities 52, 58. The presence of lipids in some, but not
all lesions was reported in RRMS subjects by Narayana et al.2, suggesting the presence of
active demyelination/remyelination.
Normal Appearing White Matter
It is now generally agreed, based on MRS3, 12, MT59, and DT60 studies that the NAWM in
patients with MS is abnormal. By exploiting the large spatial coverage allowed by multi-
voxel 1H-MRS, it has been demonstrated that metabolic abnormalities in MS patients are more
diffuse and are not restricted to lesion sites alone2, 37, 48, 61-64. 1H-MRS studies have clearly
demonstrated reduced NAA levels in NAWM, suggesting axonal/neuronal loss/dysfunction as
the underlying pathologic substrate. The reduced NAA levels on 1H-MRS have been confirmed
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by histopathology as secondary to axonal loss7, 65. In serial 1H-MRS studies, increased Cho
and lipid levels were observed from NAWM regions that subsequently went on to develop
MRI-visible lesions2, 66. These observations were consistent with MRI studies that showed
alterations in MT ratio (MTR) values prior to appearance of macroscopic lesions on MRI67.
In addition, based on increased mI68, Cr and Cho levels, increased cellularity (gliosis,
inflammation) was also postulated to occur in NAWM of MS patients48.
In a preliminary study, annual MRSI was obtained for two years from 20 patients and 10 healthy
controls to characterize the metabolite changes in early RRMS69. The concentrations of NAA,
Cr, Cho, mI and Glx were estimated in both NAWM and cortical gray matter (cGM). At
baseline, the concentration of NAA was 7% lower in NAWM of MS patients compared to the
control group and 8.7% lower in cGM. Tissue metabolite profiles did not significantly change
in MS subjects nor differed between MS and healthy controls, with the exception of NAA
concentrations that tended to recover from baseline. This study suggests that in the early phases
of the disease the neuronal/axonal damage may be at least partially reversible. Leary et al.70
have performed single voxel 1H-MRS of NAWM in PPMS (n=24) patients and in 16 age-
matched controls. NAA/Cr was significantly lower in NAWM from patients than in the white
matter from controls suggesting that axonal loss occurs in NAWM in PPMS patients and may
well be a factor associated with disease progression in this disease phenotype. No significant
difference was observed in Cr concentration between patients and controls. A multi-
center 1H-MRSI study of 40 PPMS patients showed significantly lower NAA/Cr compared
with healthy volunteers, but no significant difference between lesions and NAWM was
observed33. Twenty four of these patients had evident lipid peaks in non-lesion brain tissue
locations. Figure 3 shows, as an example, the presence of strong lipid peaks in the spectra from
NAWM of a PPMS patient. In another study, metabolite concentrations were obtained with
3D MRS and the VOI centered on the corpus callosum in 11 RRMS patients and nine
controls71. In NAWM, the concentration of NAA was observed to be 9% lower in patients
compared to controls. The same study showed an increase in Cr and Cho by 22% and 32%,
respectively. These elevated Cho levels differentiated patients from controls with 100%
specificity and higher than 90% sensitivity.
Suhy et al.72 compared metabolite levels in PPMS (n=15) and RRMS (n=13) patients with
those of controls (n=20). Cr in NAWM of PPMS patients was higher compared to controls
(P=0.035), and RRMS patients (P=0.038). Also, Cr increased in focal MRI lesions from PPMS
compared to lesions from RRMS (P=0.044) and compared to control white matter (P=0.041).
NAA was similarly reduced in NAWM from PPMS and RRMS compared to controls. The
increased Cr in NAWM in PPMS relative to RRMS is consistent with the notion that the
progressive disability in PPMS may be associated with gliosis and axonal loss, whereas
disability in RRMS may be secondary to an increased burden of acute inflammatory lesions
and axonal loss72.
Data on NAWM in clinically isolated syndrome (CIS) is limited. In 14 of 42 patients with a
single acute episode of optic neuritis, Tourbah et al.73 reported decreased NAA, increased
Cho, and the presence of lipids. In 96 patients with CIS suggestive of MS, Fernando et al.74
reported increased concentration of mI relative to controls, a finding which is suggestive for
the presence of gliosis. No significant difference in other metabolites was observed. In a
prospective study on patients with CIS suggestive of MS, Wattjes et al.75, 76 studied 31
patients and 20 controls. These authors observed 8.1% decrease in NAA (P= 0.012) in the
NAWM of patients relative to controls. However, changes in Cr, Cho, and mI were not
observed.
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Gray Matter
Cortical pathology in MS is well recognized77, 78. For a number of reasons GM lesions are
difficult to visualize on MRI. Using advanced pulse sequences, such as double inversion
recovery 79, 80 and phase sensitive inversion recovery sequence, it is possible to display some,
but not all, cortical lesions 81, 82. Involvement of GM has been demonstrated by MTR83,
DTI84, 85, and 1H-MRS studies18, 68, 86, 87.
1H-MRS of cGM is technically challenging because of its proximity to CSF and partial volume
averaging from white matter88. In addition, many of the MRS studies that employ outer volume
suppression bands for minimizing contributions from non-neural tissues make it difficult to
acquire MRS from the cGM that is close to outer surface of the brain (see Figure 1). In spite
of these limitations, MRS studies of cGM have been reported by a few groups. For example,
Sharma et al.18, by combining a double inversion recovery sequence, in which both CSF and
white matter were suppressed, demonstrated abnormalities in the cGM close to the midline
fissure in MS patients using MRSI. By combining MRSI with image segmentation, this study
has minimized contributions from WM and CSF to the VOI and showed in 52 RRMS patients
marked lipid peaks arising from the normal appearing GM, consistent with the presence of
active demyelination/remyelination. However, no significant changes in major metabolite
concentrations were observed compared to controls, suggesting no significant neuronal loss.
The lack of significant changes of metabolites in cGM is consistent with another more recent
report89.
Using short TE MRSI in 16 RRMS patients with short disease duration (mean disease duration
of 1.8 years; range 0.6-2.8 years), Kapellar et al.86 reported lower NAA (P = 0.01) and mI (P
= 0.04) in the cGM relative to controls. The reduced NAA in cGM suggested mild, but
widespread, neuronal dysfunction or loss early on in the course of the disease86. In another
study from the same group of 24 clinically early (median EDSS (Expanded Disability Status
Scale) 1.2; range 0.0-3.0) RRMS patients, Chard et al.68 reported significantly reduced NAA,
Cho, and Glx. They also observed significant correlations between MS functional composite
scores and the metabolite concentrations in cGM: Cr (r(s) = 0.524, P = 0.009), cGM Glx (r(s)
= 0.580, P = 0.003). However, no correlation was observed between clinical disability and the
level of NAA, suggesting that reduced NAA reflects neuronal dysfunction, rather than neuronal
loss early on in RRMS.
GM NAA deficits were found in the progressive form of disease, which, however, did not
significantly correlate with EDSS90. In another study, absolute concentrations of NAA, Cr,
and Cho were measured in the occipital-parietal cortex of RRMS (n=15) and SPMS (n=15)
patients and healthy subjects (n=8)91. Significantly lower values of NAA, Cr and NAA/Cr
ratio were detected in SPMS patients than in RRMS and control subjects (P<0.01), suggesting
that the pathological process in MS extends into cGM, particularly in the progressive form of
the disease. Similar observations were reported in a more recent study on a small MS
cohort87.
The levels of metabolites in the very early stage of the disease appear to be dependent on lesion
activity. In CIS suggestive of MS, Au Duong et al.88 reported that the metabolite levels in GM
are associated with the presence of enhancing lesions: when absent, there was no statistically
significant difference in the GM metabolite levels between patients and controls; when present,
a relative decrease in NAA level and an increase in Cho level were observed. This suggests
that metabolite alterations seen in the GM in the early phase of the disease may be secondary
to the inflammatory process, rather than to ‘primary’ neuronal dysfunction.
MS also affects deep GM structures92, 93. 1H-MRS studies of the thalami were performed in
RRMS (n=14) patients and age-matched healthy controls (n=14). Average NAA concentration
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in the thalami of RRMS patients was approximately 11% lower relative to controls (p<0.05).
In addition, about 25% lower mean normalized thalamic volumes was observed in patients
compared to controls (p<0.005). Decreases in thalamic NAA concentrations strongly
correlated with thalamic volume loss94. The reduction of both NAA concentration and
thalamic volume suggests a neurodegenerative component to MS that is increasingly
recognized in the disease 95.
Whole brain NAA
Recently, WBNAA as a marker of overall axonal/neuronal loss in the brain has been
proposed96. The concentration levels of WBNAA and normalized brain volumes were
significantly lower in PPMS patients than in healthy controls97. Also, WBNAA values and
normalized brain volumes were not related suggesting that MRS and atrophy assessment may
provide complementary information about the extent of brain damage in PPMS. Axonal/
neuronal damage in PPMS patients seems to occur, at least partially, independent of the burden
of MRI-visible lesions97. In another study, WBNAA levels were compared with atrophy as a
function of disease duration in a cohort of 42 RRMS patients. WBNAA levels were found to
decrease 3.6 times faster than atrophy, suggesting that neuronal/axonal dysfunction precedes
atrophy98, and that WBNAA may be a more sensitive indicator of disease progression than
lesion load or atrophy.
Although axonal pathology has been known to occur in MS, it is less clear how early in the
course of disease axonal damage starts to appear, as well as its relation to MRI-visible lesion
load. To assess this early axonal pathology, Filippi et al.99 estimated the WBNAA levels in
31 patients with CIS suggestive of MS. The mean WBNAA concentration was significantly
lower in patients compared with the controls. It was not significantly different between patients
with and without enhancing lesions at baseline MRI or between patients with and without lesion
dissemination in time. WBNAA concentrations and lesion volumes were not correlated. These
findings, consistent with both histology and localized 1H-MRS studies, suggest the presence
of widespread axonal pathology in the earliest clinically symptomatic stage of MS.
Spinal Cord
Involvement of spinal cord in MS and its potential role in patient disability has been recognized
for some time100, 101. Post-mortem examination of MS patients reported substantial atrophy
and axonal loss in the lateral columns at C3 and T2102. However, cord atrophy and total axonal
number are not strongly correlated103, suggesting that cord atrophy may underestimate axonal
loss and may not provide a valid marker of disease progression104. 1H-MRS may provide
valuable information about true axonal damage in spinal cord in MS patients. In vivo 1H-MRS
of spinal cord is quite challenging due to magnetic field inhomogeneities around the cord,
physiological movements, and small cross sectional size. Therefore, it is not surprising that
relatively few 1H-MRS studies of the spinal cord have been performed. However, Marliani et
al.105 demonstrated the feasibility of performing quantitative MRS in the cervical region on
a clinical 3 T system.
1H-MRS of normal appearing spinal cord in MS patients showed significantly reduced NAA
and altered concentration levels of other metabolites compared to healthy controls106. In one
study, MRS was used to investigate the degree of neuronal damage in the cervical cord in MS
patients. Spectra were acquired from spinal cord and brain in 11 patients and 11 controls. A
32% reduction of NAA concentration was observed in patients relative to controls (P < 0.05),
indicating significant neuronal/axonal injury. Additionally, significant cord atrophy was
observed in MS patients (15%, P < 0.001). No correlations between clinical measures and cord
atrophy or brain lesion volume were found; however, spinal cord NAA correlated with the
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cerebellar subscore of the EDSS (P < 0.005). 1H-MRS demonstrated cellular damage within
the cord over and above the tissue atrophy seen on MRI104.
In another study, Ciccarelli et al.107 acquired single-voxel 1H-MRS from the cervical cord of
14 patients with at least one lesion between C1 and C3. Thirteen age- and sex-matched control
subjects were included in the study. Patients showed reduced NAA relative to controls. In
patients, significant correlations between (i) EDSS and mI, Cho, Cr, and (ii) 9-hole peg test
(9-HPT) and Cr were observed. The concentration of mI was independently associated with
the EDSS, while Cr, NAA were independently associated with the 9-HPT. While the
limited 1H-MRS studies on cervical cord have provided useful information about tissue
damage, the full potential of 1H-MRS in spinal cord in MS patients has yet to be exploited.
Evaluation of Treatment Efficacy
Immunomodulatory therapies, including glatiramer acetate (GA), interferon (IFN)-β, and
natalizumab, are shown to be effective in reducing MRI-measured disease activity108-111.
Because of its inherent quantitative nature, MRS is ideally suited for evaluating the efficacy
of treatment. The effect of immunomodulatory treatments on brain metabolites for evaluating
treatment efficacy was studied in multiple, but small patient groups. In an open-label, non-
randomized pilot study of GA treatment in 15 RRMS patients, Narayanan et al.112 measured
NAA/Cr in a large VOI centered in the corpus callosum prior to treatment and one year after.
The untreated and treated groups had similar mean baseline NAA/Cr and EDSS. At one year,
the GA-treated group showed no change in the NAA/Cr ratio. However, the untreated group
had a small (3.5%) but significant (p=0.015) reduction in NAA/Cr. During this short period of
treatment, GA was shown to stabilize the levels of brain NAA which is consistent with the
putative neuroprotective effect of the drug, GA.
In another pilot study, Khan et al.109 obtained 1H-MRS from 18 RRMS patients before and
after treatment with GA. These patients were followed annually for two years. A small group
of four treatment naïve RRMS patients was also studied. 1H-MRSI was acquired from a large
VOI that contained both corpus callosum and adjacent white matter. The VOI included both
lesions and NAWM. The mean NAA/Cr was measured from the whole VOI and NAWM. After
two years, NAA/Cr in the GA treated group increased significantly (10.7%) in the VOI, and
by 7.1% in the NAWM. In the untreated group, NAA/Cr decreased by 8.9% at two years in
the VOI and 8.2% in the NAWM. This study showed that treatment with GA may lead to axonal
metabolic recovery and protection from sub-lethal axonal injury in RRMS patients. Long term
results of this ongoing study after 4 years of annual brain MRS examinations were reported
recently113. Compared to baseline, at year 4, patients receiving continuous GA therapy showed
an overall increase of 12.7% in NAA/Cr (P = 0.03) within the entire VOI and by 9.6% (P =
0.04) in the NAWM. Three patients in the control group who began therapy with GA during
the course of the study showed similar increases in NAA/Cr after the first year of therapy.
These data support the notion of a possible sustained effect of GA in RRMS and the feasibility
of employing MRS in long-term investigative studies of MS113.
In a multi-center longitudinal MRSI study, the efficacy of GA treatment in 58 PPMS patients
was investigated annually for three years114. This patient population was a subcohort of the
PROMiSe trial patients115. Quantitative NAA/Cr and Cho/Cr were compared between GA-
treated and placebo-treated PPMS patients. This study failed to demonstrate a significant effect
of GA on the metabolite concentrations. There were no significant changes in metabolite
concentrations in untreated PPMS patients over three years. These findings are different from
those in RRMS described above and may suggest that substantive decreases in NAA/Cr may
have occurred at an earlier stage of disease in PPMS and treatment with GA may not result in
improvement of the metabolite profile114.
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Longitudinal MRS studies have been carried out in 10 RRMS patients who, after baseline
examination, received interferon β-1b. Spectra were acquired up to 34 months at different time
points (from 8-20 time points), and absolute concentrations of NAA, Cr, and Cho were
determined in a large non-enhancing lesion and contralateral NAWM116. The concentrations
of Cho and Cr were found to be higher in MS than in healthy controls 116. These studies,
except in one out of 10 patients, failed to demonstrate any effect of interferon β-1b on the
metabolic levels.
1H-MRS has also been used to investigate the modifications of brain metabolites, in the initial
phase of interferon β-1a treatment117. This study was performed on 5 RRMS patients who
were treated with intramuscular IFN β-1a for six months and 5 untreated patients. Patients were
evaluated at the beginning of the study and in the first, third, and sixth month of treatment. In
white matter lesions, NAA, Cho, Cr, and mI peaks did not vary significantly over the entire
period of study in the untreated group. In the treated group, there was a significant increase in
Cho at the first month relative to the pretreatment period, and continued to increase at months
3 and 6 (p<0.001). A slight but not statistically significant increase in Cho was also found in
the NAWM from the patients treated with IFN β-1a.
In a small pilot study, 1H-MRS was performed in 10 RRMS patients before and after one year
of treatment with subcutaneous interferon β-1b. NAA/Cr was measured in a large central brain
volume118. These measurements were compared with those from six untreated patients
selected for similar range of EDSS scores and mean NAA/Cr at baseline. NAA/Cr in the treated
group showed an increase of 5.5% at 12 months of therapy, while this ratio decreased in the
untreated group, but not significantly. NAA/Cr was significantly higher in the treated group at
12 months than in the untreated group118, suggesting an effect of interferon β-1b in restoring
neural integrity.
Unfortunately, many of these studies are based on small patient populations followed over
relatively short intervals. Lack of standardized acquisition and analysis protocols makes it very
difficult to evaluate the results critically.
Conclusions
1H-MRS is a valuable tool that could contribute in objectively following the evolution of MS,
to the understanding of its pathogenesis, evaluating disease severity, establishing prognosis,
and assessing the efficacy of therapeutic interventions. Some of the most compelling evidences
that axonal loss is a major cause of disability in MS has come from 1H-MRS studies which
show reduced NAA levels in brain of these patients. 1H-MRS studies have shown that axonal
damage is an early event that occurs before the formation of MRI-visible lesions. However, a
number of technical factors that include poor SNR, long acquisition times, poor spatial
resolution, limited spatial coverage, and complex data processing have so far limited the use
of 1H-MRS in routine clinical practice. Recent developments of high field MRI scanners for
improved SNR and spectral resolution, introduction of parallel imaging, fast analysis
techniques, and the availability of free analysis tools should greatly facilitate a more widespread
use of 1H-MRS in the diagnosis and management of MS. Another aspect of MRS that needs
to be addressed is the standardization of both acquisition and analysis protocols. A first step
towards achieving the standardization, based on single voxel MRS, has recently been
proposed13. While this is an appropriate first step, standardized protocols that include multi-
voxel MRS for increased spatial coverage and exploit the full potential of MR hardware and
software are needed.
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Figure 1.
Application of outer volume suppression bands to minimize extrameningeal tissue
contamination. Left: Eight outer volume suppression bands on one of the five images (each, 3
mm thickness) that represent the spectroscopic volume of interest (15 mm thickness); right:
localized image(15 mm slice thickness with the application of the suppression bands) from
which 1H-MRSI is acquired.
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Figure 2.
Single voxel spectra with short TE (=35 msec) and long TE (=144 msec) acquired from white
matter region of a normal brain at 3.0 Tesla. The large number of metabolite peaks with broad
baseline can be observed in the short TE spectrum (top). In contrast, long TE spectrum (bottom)
has relatively flat baseline and fewer metabolite peaks. See text for abbreviations
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Figure 3.
Abnormal peaks in normal-appearing white matter of a patient with primary progressive
multiple sclerosis. Top: Left: One of the five MR images (each 3 mm thick) of the cross-section
of the brain location from where the 1H-MRSI data acquired. Right: Collapsed image
representing the spectroscopic volume of interest (thickness=15 mm). The small grid on the
collapsed image represents the spatial location shown in the bottom panel. Strong lipid peaks
can be observed in these spectra. The spectra were acquired at TE of 30 ms.
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